Press release
Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epidemiology, and Market Outlook
Metabolic Dysfunction-Associated Steatohepatitis
MASH/NASH is a major global health burden, with prevalence rising due to the global obesity epidemic and sedentary lifestyles. If untreated, it can progress to cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Until recently, no approved drugs were available for MASH, but in the past few years, significant progress has been made with novel therapies targeting metabolic and fibrotic pathways.
The MASH/NASH market is rapidly expanding with the approval of innovative drug classes such as FXR agonists, GLP-1 receptor agonists, and PPAR agonists, alongside ongoing clinical trials for FGF analogs and combination therapies. Supportive government initiatives, rising healthcare investments, and growing patient awareness are expected to drive strong market growth between 2025 and 2034.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71123
In a Nutshell
• Market Size (2024): USD 3.2 billion
• Forecast (2034): USD 7.8 billion
• CAGR (2025-2034): 9.1%
• Key Growth Driver: Rising obesity and diabetes prevalence, coupled with first-in-class drug approvals for MASH/NASH
• Top Region: North America dominates due to early drug adoption, strong diagnostic infrastructure, and high obesity prevalence
• Top Application: Hospitals and specialty clinics dominate, as advanced patients require integrated hepatology and endocrinology care
• Leading Players: Madrigal Pharmaceuticals, Novo Nordisk, Intercept Pharmaceuticals, Gilead Sciences, Novartis, Pfizer, Takeda, Bristol Myers Squibb, AstraZeneca, Eli Lilly
• Major Trends: Launch of first approved drugs, growth of GLP-1 therapies, expansion of biomarker-based diagnostics, and policy support for liver health
• Recent Developments (2025): Pharma leaders launched new drug classes, initiated late-stage trials, and expanded affordability programs globally
Market Overview
The MASH/NASH market is undergoing a transformational phase, shifting from an unmet-need area to one of the most competitive and innovative drug markets in hepatology.
Growth is driven by:
• Rising prevalence of obesity, diabetes, and metabolic syndrome globally
• Approval and commercialization of first-in-class therapies targeting fibrosis and metabolic dysfunction
• Increasing adoption of biomarker-based diagnostics for early detection
• Expanding clinical research into combination therapies addressing multiple disease pathways
• Strong investment by biopharma companies and government programs
Between 2025 and 2034, the market will be driven by drug uptake, expansion in emerging economies, and integration of digital health tools to monitor liver function and patient adherence.
Key Market Drivers
1. Global Obesity & Diabetes Epidemic
MASH prevalence directly correlates with rising obesity and type 2 diabetes rates.
2. First Drug Approvals
Novel drug launches mark a paradigm shift in treatment adoption and commercial growth.
3. Advances in Biomarker Diagnostics
Non-invasive tests (NITs) and imaging tools improve early diagnosis and monitoring.
4. Government & NGO Support
Public health campaigns and rare liver disease frameworks promote awareness and treatment adoption.
Key Restraints and Challenges
• High Therapy Costs: Novel drugs are expensive, limiting adoption in developing economies.
• Asymptomatic Early Disease: Many patients remain undiagnosed until advanced fibrosis or cirrhosis.
• Competition & Pipeline Uncertainty: Multiple drug classes compete, and long-term efficacy is still under evaluation.
• Regional Inequalities: Access to therapies and diagnostics remains limited in low-income countries.
Opportunities & Trends
• GLP-1 Receptor Agonists: Widely used in diabetes and obesity, GLP-1s show strong efficacy in MASH patients.
• Combination Therapies: Dual approaches targeting metabolic dysfunction and fibrosis are gaining traction.
• Digital Liver Health Solutions: Remote monitoring and AI-based imaging tools enhance treatment adherence.
• Emerging Market Expansion: Rising obesity rates in APAC and LATAM create significant growth opportunities.
Market Segmentation
By Drug Class
• FXR Agonists
• GLP-1 Receptor Agonists
• PPAR Agonists
• FGF21/FGF19 Analogs
• Others (Pipeline agents, combination drugs)
By Disease Stage
• Fibrosis Stage F1-F2
• Fibrosis Stage F3
• Cirrhotic NASH (F4)
By End-User
• Hospitals
• Specialty Clinics
• Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/71123/metabolic-dysfunction-associated-steatohepatitis-market
Regional Insights
North America
North America dominates the MASH market with early FDA approvals, high obesity and diabetes prevalence, and advanced hepatology infrastructure. The U.S. leads in adoption of GLP-1 therapies and clinical trial activity.
Europe
Europe holds the second-largest share, with Germany, France, and the UK leading adoption. Strong reimbursement policies and biomarker adoption enhance patient access.
Asia-Pacific
APAC is projected to record the fastest CAGR, fueled by high obesity and diabetes prevalence in China, India, and Japan, growing healthcare investment, and pharma partnerships.
Latin America
Moderate growth is expected in Brazil and Mexico, with obesity-driven liver disease prevalence rising and healthcare infrastructure expanding.
Middle East & Africa
MEA remains smaller but is expanding steadily through GCC obesity management programs and NGO liver health initiatives.
Competitive Landscape
The MASH market is highly competitive and innovation-driven, with global pharma leaders advancing multiple drug classes.
Key Players (as per report):
• Madrigal Pharmaceuticals
• Novo Nordisk
• Intercept Pharmaceuticals
• Gilead Sciences
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company
• Bristol Myers Squibb
• AstraZeneca
• Eli Lilly
These companies are prioritizing pipeline development, clinical trial collaborations, and patient affordability initiatives to expand therapy adoption.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71123
Recent Developments (2025)
1. Madrigal Pharmaceuticals (Jan 2025): Expanded commercial rollout of its FDA-approved MASH therapy in the U.S.
2. Novo Nordisk (Feb 2025): Reported strong Phase III trial results for semaglutide in advanced MASH patients.
3. Gilead Sciences (Mar 2025): Launched global trial of a combination regimen targeting fibrosis regression.
4. Eli Lilly (Apr 2025): Introduced a new GLP-1 drug for obesity and MASH management in APAC markets.
5. Intercept Pharmaceuticals (May 2025): Expanded European access program for its FXR agonist following regulatory clearance.
Events and Implications
• First Drug Approvals Change Market Dynamics: MASH shifts from unmet need to competitive therapy market.
• GLP-1s Dominate Market Momentum: Diabetes and obesity overlap strengthens GLP-1 adoption.
• Biomarker Integration Accelerates: Non-invasive testing enhances early diagnosis and monitoring.
• Global Access Challenges Persist: Developed markets lead, while affordability in APAC & LATAM is critical.
Conclusion
The Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market is entering a transformative decade between 2025 and 2034, driven by drug approvals, obesity and diabetes prevalence, biomarker integration, and strong pharma R&D pipelines.
North America and Europe dominate revenues, while Asia-Pacific emerges as the fastest-growing region due to its obesity burden and healthcare expansion.
With Madrigal, Novo Nordisk, Gilead, Eli Lilly, and Intercept leading innovation, the MASH market is set for exponential growth, marking a paradigm shift in liver disease management and creating new opportunities for patients and stakeholders worldwide.
This report is also available in the following languages : Japanese (代謝機能障害関連脂肪肝炎市場), Korean (대사 기능 장애 관련 지방간염 시장), Chinese (代谢功能障碍相关脂肪性肝炎市场), French (Marché de la stéatohépatite associée à un dysfonctionnement métabolique), German (Markt für metabolische Dysfunktion-assoziierte Steatohepatitis), and Italian (Mercato della steatoepatite associata alla disfunzione metabolica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71123/metabolic-dysfunction-associated-steatohepatitis-market#request-a-sample
Our More Reports:
Neuroendocrine Tumors (NETs) Market
https://exactitudeconsultancy.com/reports/71255/neuroendocrine-tumors-nets-market
Neurofibrosarcoma Market
https://exactitudeconsultancy.com/reports/71256/neurofibrosarcoma-market
Non-Hodgkin's Lymphoma Market
https://exactitudeconsultancy.com/reports/71257/non-hodgkin-s-lymphoma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epidemiology, and Market Outlook here
News-ID: 4158156 • Views: …
More Releases from Exactitude Consultancy
Irritable Bowel Syndrome (IBS) Market Growth, Trends, Consumer Demand and Key Op …
Introduction
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, altered bowel habits (constipation, diarrhea, or mixed), and recurrent discomfort. While not life-threatening, IBS significantly reduces quality of life and is often associated with psychological distress and comorbid conditions such as anxiety and depression.
The global IBS patient pool is increasing due to stressful lifestyles, dietary changes, rising prevalence of gastrointestinal disorders, and greater awareness leading…
Gastroparesis Market Set to Witness Significant Growth by 2025-2034
Introduction
Gastroparesis is a chronic gastrointestinal motility disorder characterized by delayed gastric emptying without mechanical obstruction. It leads to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal discomfort, often resulting in malnutrition and reduced quality of life.
The most common cause of gastroparesis is diabetes mellitus, particularly poorly controlled type 1 and type 2 diabetes. Other causes include post-surgical complications, neurological conditions, and idiopathic cases. With the global rise in…
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Insights and Future Outl …
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Outlook 2024-2034: Advancing Diagnostics and Targeted Therapies to Drive Growth
Introduction
Gastrointestinal Neuroendocrine Tumors (GI-NETs) are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract, including the stomach, small intestine, colon. These tumors can be functioning (hormone-secreting) or non-functioning, often leading to late diagnoses. Symptoms vary widely and may include abdominal pain, diarrhea, flushing, and in advanced cases, metastasis to the liver.
Historically considered rare and…
Liver Cirrhosis Market Trends, Epidemiology and Future Outlook
Liver cirrhosis is a chronic, progressive liver disease characterized by scarring (fibrosis) and the gradual replacement of healthy liver tissue with scar tissue. This disrupts normal liver function, leading to portal hypertension, liver failure, and complications such as ascites, variceal bleeding, hepatic encephalopathy, and hepatocellular carcinoma (HCC).
The global burden of cirrhosis is rising due to the increasing prevalence of alcoholic liver disease, chronic hepatitis B and C, and non-alcoholic fatty…
More Releases for MASH
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is becoming an increasingly urgent global public health issue. This progressive liver disease, characterized by fat buildup in the liver unrelated to alcohol consumption, can lead to inflammation (hepatitis), fibrosis, cirrhosis, and eventually liver cancer.
Download Strategic Sample PDF: https://datamintelligence.com/strategic-insights/sample/metabolic-dysfunction-associated-steatohepatitis-mash?ophp
Akero Therapeutics Completes Enrollment for Double-Blind Phase III SYNCHRONY Real-World Study of Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD…
Pepper Mash Market Size Estimated to grow USD 0.517 Billion by 2032
Pepper Mash Market Overview
The pepper mash market is a dynamic segment of the global food industry, characterized by its rich flavor profiles and wide-ranging applications. Pepper mash, a key ingredient in the production of hot sauces, seasonings, and processed foods, has gained significant traction due to its ability to impart heat and complexity to various dishes. This blog delves into the market overview, competitive landscape, key drivers, segmentation, and regional…
Fermented Pepper Mash Market Revenue, Insights, Overview, Outlook, Analysis | Va …
Fermented Pepper Mash Market
Fermented Pepper Mash is one of the most commonly used ingredients in kitchens and hot sauce manufacturers. This product is ideal for making medium-heat hot sauces and marinades. One can add small amounts to stews, soups and pastes to give them a mild flavor. Additionally, people can create their own homemade sauce by adding garlic, onions, vinegar, sugar, lemon juice, and more ingredients.
According to new survey, global…
Pepper Mash Market Production, Consumption, Export-Import Analysis Through 2030
** Market Overview **
Pepper mash refers to a mixture of ground black peppercorns in brine, vinegar or other solutions that is used to impart flavor, spice and heat to various food products. It is used in sauces, marinades, snacks, meat products and other culinary applications across the world.
The growth of the global pepper mash market is being driven by rising demand for convenience foods, growing adoption of international cuisines and…
Mash Tun Media: New UK Marketing Agency working exclusively with breweries
Mash Tun Media, the latest and most focused Digital Marketing Agency for Microbreweries has been developed and launched by the team at Future State Media.
Developing niche-specific skills and understanding of the unique demands of the microbrewing market has been a passion of the team at Future State Media for the past year. Working in the brewing niche has aligned so well with existing successful projects where the team had…
TV Antennas Market Size Mash up 2020-2025 - Worldwide Growth and Services Overvi …
(United States, OR Poland) : A complete research offering of a comprehensive analysis of the market share, size, recent developments, and trends can be availed in this latest report by Big Market Research. As per the report, the Global TV Antennas Market is anticipated to witness significant growth during the forecast period from 2020 to 2025.
The report provides brief summary and detailed insights into the market by collecting data…
